Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vyne Therapeutics Inc VYNE

Healthcare
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its... see more

Recent & Breaking News (NDAQ:VYNE)

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

GlobeNewswire May 18, 2022

VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022

VYNE Hosting Key Opinion Leader Event on Novel InhiBET(TM) BET Inhibitor Platform

GlobeNewswire May 10, 2022

VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th

GlobeNewswire May 6, 2022

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

GlobeNewswire April 7, 2022

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

GlobeNewswire March 30, 2022

VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 17, 2022

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

GlobeNewswire March 7, 2022

VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference

GlobeNewswire March 3, 2022

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

GlobeNewswire January 19, 2022

VYNE Therapeutics Divests Topical Minocycline Assets

GlobeNewswire January 13, 2022

VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event

GlobeNewswire January 3, 2022

VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

GlobeNewswire November 18, 2021

VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 10, 2021

Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study

GlobeNewswire November 4, 2021

VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

GlobeNewswire October 28, 2021

Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies

GlobeNewswire October 26, 2021

VYNE Therapeutics Announces Formation of Scientific Advisory Board

GlobeNewswire October 21, 2021

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

GlobeNewswire October 19, 2021

VYNE Therapeutics Announces its China Partner's Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne

GlobeNewswire October 5, 2021